Pharmaceutical

Rosalind Franklin University is building the $50 million Innovation and Research Park in North Chicago, Ill. The four-story, 100,000-sf facility will provide leading-edge research labs, business incubator space, meeting rooms, and common areas. The project will promote collaboration among faculty, industry scientists, and biotech entrepreneurs in order to accelerate the discovery and commercialization of new medical treatments and therapeutics.

Autolus Therapeutics has signed a long-term, full-building lease with Alexandria Real Estate Equities for the construction and development of a build-to-suit facility in Rockville, Md. Located in the Shady Grove Life Sciences Center, the 85,000-sf project will accommodate the company's U.S. headquarters and a commercial-scale manufacturing center for cell therapies. Occupancy is expected in 2021.

EMD Serono is planning to construct a $70 million R&D facility on its existing campus in Billerica, Mass. Supporting research programs in oncology, immuno-oncology, and immunology, the 145,000-sf building will accommodate wet labs, offices, collaboration spaces, and a cafeteria. Designed to attain LEED and WELL certification, the project will provide a healthy and sustainable environment for approximately 400 employees. Completion is expected in 2021. EMD Serono is the biopharmaceutical business of Merck KGaA, based in Darmstadt, Germany.

Catalent is initiating an expansion of its biologics manufacturing operations. The global biotechnology company will construct a 60,000-sf facility on its existing campus in Madison, Wis. The project is slated for completion by 2021 and represents an investment of $100 million over the next three years. Catalent will also invest $100 million to increase its manufacturing capacity in Bloomington, Ind.

Merck began construction in January of 2019 on a $300 million pharmaceutical formulation and process development facility in Rahway, N.J. Designed for maximum flexibility, the Formulation Laboratory Experimental (FLEx) Center will feature modular cleanrooms and cGMP manufacturing suites to support multiple modalities including large and small molecule, sterile, and oral solid-dosage products.

Brammer Bio is developing two gene therapy manufacturing facilities in Massachusetts. The company will build out 35,000 sf in an existing 50,000-sf structure in Lexington to create a cGMP manufacturing and quality control operations center. Additionally, Brammer will renovate 8,000 sf in its 66,000-sf commercial cGMP plant in Cambridge to create new production suites to support manufacturing capacity expansion. DPS Group is providing architectural and engineering services for both projects, which are slated for completion in mid-2019.

Fujifilm Cellular Dynamics is creating a stem cell manufacturing center in Madison, Wis. Located in the University Research Park, the $21 million project involves the renovation of 31,500 sf in a facility near the company's existing lab and office building. The completed biomanufacturing plant will meet the requirements of the U.S. Food and Drug Administration. Completion is expected by March of 2020.

EMD Serono’s Project SagaMORE has been named the 2018 Green Building of the Year by the Massachusetts chapter of the U.S. Green Building Council. Located on EMD Serono's biopharmaceutical manufacturing campus in Billerica, the two-story, 30,000-sf addition offers open-plan work areas, a central auditorium, and numerous meeting spaces to support the development of advanced medical therapies. The $12 million project has jointly achieved WELL Gold certification for New & Existing Construction.

Merck will break ground in January of 2019 on a $28 million pharmaceutical research and distribution center in Visalia, Calif. The 123,332-sf facility will be located in the Visalia Industrial Park and can be expanded by 160,000 sf to accommodate future growth. The developer for the project is Scannell and completion is expected in late 2019. Merck is based in Darmstadt, Germany.

Sanofi announced the lease of 900,000 sf in two buildings in the Cambridge Crossing development in December of 2018. The French pharmaceutical manufacturer will occupy approximately a fifth of the 45-acre campus spanning Cambridge, Boston, and Somerville. The project will provide collaborative laboratory and office space for 2,700 Sanofi employees.

The Vaccines Manufacturing Innovation Centre is planning to create a £66 million research and production facility in the United Kingdom. Located in the Oxford Science Park, the project will support the development and manufacturing of vaccines for clinical trials and epidemic threat mitigation, as well as the creation of gene therapy technologies and personalized medicine solutions.

Mustang Bio completed construction of its 27,000-sf cell therapy manufacturing center in November of 2018. Located in the UMass Medicine Science Park in Worcester, the facility supports the clinical development and commercialization of Mustang's CAR-T and gene therapy product candidates. Accommodating proprietary cell therapy research, the project involved the renovation of labs and offices, as well as the conversion of existing labs to create three cGMP ISO7 clinical production areas.

Children's National Health System broke ground in late November of 2018 on the Research and Innovation Campus in Washington. The project includes the renovation of four existing buildings located on 12 acres on the former Walter Reed Medical Center Campus. A 333,000-sf research and innovation facility will provide 158,000 sf of laboratory space for the study of pediatric genomics and precision medicine. The project will include a business incubator and 175,000 of shell space to accommodate future growth. Completion is expected in 2020.

Children's Hospital of Philadelphia completed construction of the $75 million Clinical Vector Core in November of 2018. Located on the basement level of the Colket Translational Research Building, the project provides laboratories, offices, four production suites, and cleanrooms for the manufacture of gene therapy agents for clinical trials. The 15,000-sf facility features robust environmental controls and was built at a cost of $44 million. The Clinical Vector Core is part of the Raymond G.

AbbVie signed a long-term lease in November of 2018 for 480,000 sf in the Gateway of Pacific development in South San Francisco. The facility will be located in a 12-story building currently being constructed by BioMed Realty. Gateway of Pacific is being delivered in two phases, with the first phase comprising 555,000 sf of lab, research, office, and amenity space. Completion is expected in late 2019. The second phase will provide an additional 431,000 sf of lab, office, and parking space and is slated for completion in late 2021.